[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340508-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340508-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","oncolytic-virotherapies-and-adjuvant-gut-microbiome-therapeutics-to-enhance-efficacy-against-malignant-gliomas","Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas","","Glioblastoma (GBM) is the most prevalent malignant brain tumor, and current standard treatments provide limited survival benefits. Oncolytic virotherapy uses engineered or non-engineered viruses that selectively infect and lyse cancer cells, while genetic advances improve targeting and broaden the therapeutic window. Efficacy may be increased by combining OVs with immunotherapy, chemotherapy, or radiation. Emerging evidence indicates that modulating the gut microbiome can strengthen immune responses and enhance therapeutic outcomes, and this narrative review summarizes key technologies for improving GBM responses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/oncolytic-virotherapies-and-adjuvant-gut-microbiome-therapeutics-to-enhance-efficacy-against-malignant-gliomas/340508/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/oncolytic-virotherapies-and-adjuvant-gut-microbiome-therapeutics-to-enhance-efficacy-against-malignant-gliomas/340508.png","ImageObject",300,407,{"name":42,"@type":43},"Evangeline","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is glioblastoma treatment still challenging despite current standard-of-care therapies?","Question",{"text":63,"@type":64},"Current GBM therapies such as surgery, chemotherapy, and radiation provide relatively limited effectiveness, leading to poor survival outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do oncolytic virotherapies work against malignant gliomas?",{"text":68,"@type":64},"Oncolytic viruses infect and lyse cancer cells, aiming to destroy tumors without harming healthy cells, and genetic modifications can improve targeting and add therapeutic genes.",{"name":70,"@type":61,"acceptedAnswer":71},"How can combining oncolytic virotherapy with other treatments improve outcomes?",{"text":72,"@type":64},"Combining OVs with immunotherapy, chemotherapy, or radiation can enhance efficacy and overall survival, addressing limitations of monotherapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340508,1790211789,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","Review  \nOncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas  \nNatalie M. Meléndez-Vázquez 1, Candelaria Gomez-Manzano 2 and Filipa Godoy-Vitorino 1, *  \nCitation: Meléndez-Vázquez, N.M.; Gomez-Manzano, C.; Godoy-Vitorino, F. Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas. Viruses 2024, 16, 1775. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/v16111775](10.3390/v16111775)  \nAcademic Editors: Arianna Calistriand Sandra Tuyaerts  \nReceived: 11 October 2024  \nRevised: 8 November 2024  \nAccepted: 11 November 2024  \nPublished: 14 November 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Microbiology and Medical Zoology, University of Puerto Rico-Medical Sciences Campus, San Juan, PR 00918, USA; [natalie.melendez2@upr.edu](natalie.melendez2@upr.edu)  \n2 Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; [cmanzano@mdanderson.org](cmanzano@mdanderson.org)  \n* [Correspondence: filipa.godoy@upr.edu](Correspondence: filipa.godoy@upr.edu); Tel.: +1-787-758-2525 (ext. 2096)  \nAbstract: Glioblastoma (GBM) is the most prevalent malignant brain tumor. Current standard-of-care treatments offer limited benefits for patient survival. Virotherapy is emerging as a novel strategy to use oncolytic viruses (OVs) for the treatment of GBM. These engineered and non-engineered viruses infect and lyse cancer cells, causing tumor destruction without harming healthy cells. Recent advances in genetic modifications to OVs have helped improve their targeting capabilities and introduce therapeutic genes, broadening the therapeutic window and minimizing potential side effects. The efficacy of oncolytic virotherapy can be enhanced by combining it with other treatments such as immunotherapy, chemotherapy, or radiation. Recent studies suggest that manipulating the gut microbiome to enhance immune responses helps improve the therapeutic efficacy of the OVs. This narrative review intends to explore OVs and their role against solid tumors, especially GBM while emphasizing the latest technologies used to enhance and improve its therapeutic and clinical responses.  \nKeywords: viroimmunotherapy; therapeutic efficacy; gut microbiome; glioblastoma; combinatory therapies  \n1. Introduction  \nGlioblastoma (GBM) is the most common primary malignant brain tumor and one of the most invasive cancers worldwide. Current therapies against GBM, including surgical resection, chemotherapy, and radiation, have proven to be relatively ineffective, resulting ina median survival of 15 months post-diagnosis [1–3] and a 5-year survival rate of 6.8%[3] . Treatment advances against this solid tumor include several types of immunotherapies and targeted therapies. Among these, immune checkpoint inhibitors (ICIs) have proven to be quite unsuccessful in patients with GBM [4,5] .  \nTo target the poor survival prognosis associated with malignant gliomas, the development of new therapies is imperative. To tackle this problem, a special type of immunotherapy known as oncolytic viral therapy has shown promising results in preclinical and clinical studies [6] . Advances in the oncolytic viral therapy field have led to US Food and Drug Administration (FDA) approval of talimogene laherparepvec (T-VEC), a modified herpes simplex virus (HSV) type 1 with cancer selectivity, to treat another type of solid tumor, metastatic melanoma [7] . Although oncolytic viruses (OVs) are promising bio-therapeutic agents [8], an important challenge arises with their efficacy due to their high immunogenic","cbCaidAYcSpw9sel","https://ap.wps.com/l/cbCaidAYcSpw9sel","pdf",1624525,23,"English","# Introduction\n## Oncolytic viral therapy as emerging strategy\n## Role of gut microbiome in cancer therapy response","[{\"question\":\"Why is glioblastoma treatment still challenging despite current standard-of-care therapies?\",\"answer\":\"Current GBM therapies such as surgery, chemotherapy, and radiation provide relatively limited effectiveness, leading to poor survival outcomes.\"},{\"question\":\"How do oncolytic virotherapies work against malignant gliomas?\",\"answer\":\"Oncolytic viruses infect and lyse cancer cells, aiming to destroy tumors without harming healthy cells, and genetic modifications can improve targeting and add therapeutic genes.\"},{\"question\":\"How can combining oncolytic virotherapy with other treatments improve outcomes?\",\"answer\":\"Combining OVs with immunotherapy, chemotherapy, or radiation can enhance efficacy and overall survival, addressing limitations of monotherapy.\"}]","Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas | PDF",1790036946,58,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c9cbd2345b8fe033e4bfef4e5a3dcbc.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/410969b2a14a7c3c24b1dc1daae62cba.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56c17642807f506d8849535f697bdc9d.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28c90d6f33cb05abe885d96db9877454.webp",980,1385]